Semi-synthetic cannabinoid
Narcotic: named in scheduleH4-CBDTetrahydrocannabidiol (H4-CBD)
Aliases.Tetrahydrocannabidiol · H4-cannabidiol · H4CBD
Hydrogenated CBD - a saturated version of the molecule with a slight CB1 affinity. Largely non-intoxicating.
Updated on
Level of detail
Identifiers
- Formula
- C₂₁H₃₄O₂
- CAS
- 4460-20-2
- PubChem CID
- 616324
- First described
- 1940 (Todd) · réémergence commerciale 2022
- Origin
- Semi-synthetic
In plain terms
H4-CBD is CBD to which hydrogen has been added. It binds CB1 a little more than CBD, far less than THC, and it has almost no clinical research behind it.
Receptors and activity
- CB1Partial agonist
- CB2Partial agonist
- TRPV1Modulator
- 5-HT1AAgonist
- Agonist
- Partial agonist
- Antagonist
- Modulator
- Inverse agonist
Hover over a row for the precise value (Ki, EC50…)
Subjective signature
Hover over an axis to read its definition.
- Calm80
- Clarity60
- Sleep75
- Appetite30
- High30
Editorial estimate, not clinical.
Pharmacology
H4-CBD is obtained by hydrogenating cannabidiol, which saturates the terpene ring. The measured CB1 affinity (Ki ≈ 145 nM) is well above CBD's, without approaching THC's partial-agonist profile. The molecule is recent and the human data is essentially absent: no clinical trial establishes its safety profile, which is the point to hold on to before any commercial claim.
Route of preparation (chemical process)
Catalytic hydrogenation of CBD
Legal framework
France
Unclear · not scheduled as of the last review
European Union
Varies by member state
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Structural classification
- Class
- Semi-synthetic cannabinoid
- Origin
- Semi-synthetic
- Status
- Narcotic: named in schedule
Structured data
- SMILES
- CCCCCC1=CC(=C(C(=C1)O)C2CC(CCC2C(C)C)C)O
- Formula
- C21H34O2
- CAS
- 4460-20-2
- PubChem CID
- 616324
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.